[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
doi: 10.3322/caac.21660
|
[2] |
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454. DOI: 10.1038/nature25183.
doi: 10.1038/nature25183
|
[3] |
Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38. DOI: 10.1186/s12943-018-0777-1.
doi: 10.1186/s12943-018-0777-1
|
[4] |
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128. DOI: 10.1126/science.aaa1348.
doi: 10.1126/science.aaa1348
pmid: 25765070
|
[5] |
马骏, 张红颖, 吴艾平, 等. 免疫检查点抑制剂在肺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 683-687. DOI: 10.3760/cma.j.cn371439-20201231-00135.
doi: 10.3760/cma.j.cn371439-20201231-00135
|
[6] |
Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis[J]. JAMA Oncol, 2019, 5(8): 1195-1204. DOI: 10.1001/jamaoncol.2019.1549.
doi: 10.1001/jamaoncol.2019.1549
|
[7] |
Zhang Z, Zheng L, Yu Y, et al. Involvement of SAMHD1 in dNTP homeostasis and the maintenance of genomic integrity and oncotherapy (review)[J]. Int J Oncol, 2020, 56(4): 879-888. DOI: 10.3892/ijo.2020.4988.
doi: 10.3892/ijo.2020.4988
pmid: 32319570
|
[8] |
Rentoft M, Lindell K, Tran P, et al. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance[J]. Proc Natl Acad Sci U S A, 2016, 113(17): 4723-4728. DOI: 10.1073/pnas.1519128113.
doi: 10.1073/pnas.1519128113
pmid: 27071091
|
[9] |
Clifford R, Louis T, Robbe P, et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage[J]. Blood, 2014, 123(7): 1021-1031. DOI: 10.1182/blood-2013-04-490847.
doi: 10.1182/blood-2013-04-490847
pmid: 24335234
|
[10] |
Felip E, Gutiérrez-Chamorro L, Gómez M, et al. Modulation of DNA damage response by SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase (SAMHD1) determines prognosis and treatment efficacy in different solid tumor types[J]. Cancers (Basel), 2022, 14(3): 641. DOI: 10.3390/cancers14030641.
doi: 10.3390/cancers14030641
|
[11] |
Wu Y, Niu Y, Wu Y, et al. SAMHD1 can suppress lung adenocarcinoma progression through the negative regulation of STING[J]. J Thorac Dis, 2021, 13(1): 189-201. DOI: 10.21037/jtd-20-1889.
doi: 10.21037/jtd-20-1889
pmid: 33569199
|
[12] |
Bonifati S, Daly MB, St Gelais C, et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells[J]. Virology, 2016, 495: 92-100. DOI: 10.1016/j.virol.2016.05.002.
doi: 10.1016/j.virol.2016.05.002
pmid: 27183329
|
[13] |
Kodigepalli KM, Bonifati S, Tirumuru N, et al. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis[J]. Cell Cycle, 2018, 17(9): 1124-1137. DOI: 10.1080/15384101.2018.1480218.
doi: 10.1080/15384101.2018.1480218
pmid: 29911928
|
[14] |
Daddacha W, Koyen AE, Bastien AJ, et al. SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination[J]. Cell Rep, 2017, 20(8): 1921-1935. DOI: 10.1016/j.celrep.2017.08.008.
doi: S2211-1247(17)31096-3
pmid: 28834754
|
[15] |
Coquel F, Silva MJ, Técher H, et al. SAMHD1 acts at stalled replication forks to prevent interferon induction[J]. Nature, 2018, 557(7703): 57-61. DOI: 10.1038/s41586-018-0050-1.
doi: 10.1038/s41586-018-0050-1
|
[16] |
Coquel F, Neumayer C, Lin YL, et al. SAMHD1 and the innate immune response to cytosolic DNA during DNA replication[J]. Curr Opin Immunol, 2019, 56: 24-30. DOI: 10.1016/j.coi.2018.09.017.
doi: S0952-7915(18)30050-5
pmid: 30292848
|
[17] |
Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx[J]. Nature, 2011, 474(7353): 654-657. DOI: 10.1038/nature10117.
doi: 10.1038/nature10117
|
[18] |
Park K, Ryoo J, Jeong H, et al. Aicardi-Goutières syndrome-asso-ciated gene SAMHD1 preserves genome integrity by preventing R-loop formation at transcription-replication conflict regions[J]. PLoS Genet, 2021, 17(4): e1009523. DOI: 10.1371/journal.pgen.1009523.
doi: 10.1371/journal.pgen.1009523
|
[19] |
Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression[J]. Cell Rep, 2017, 19(6): 1189-1201. DOI: 10.1016/j.celrep.2017.04.031.
doi: S2211-1247(17)30525-9
pmid: 28494868
|
[20] |
Herold N, Rudd SG, Ljungblad L, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies[J]. Nat Med, 2017, 23(2): 256-263. DOI: 10.1038/nm.4265.
doi: 10.1038/nm.4265
pmid: 28067901
|
[21] |
Li Z, Huan C, Wang H, et al. TRIM21-mediated proteasomal degradation of SAMHD1 regulates its antiviral activity[J]. EMBO Rep, 2020, 21(1): e47528. DOI: 10.15252/embr.201847528.
doi: 10.15252/embr.201847528
|